Chimeric Therapeutic (ASX:CHM)
Historical Yield (%)
Short Sell (%)
GICS Industry Group
GICS Sub-Industry Group
EBITDA Margin (%)
EBIT Margin (%)
NPAT Margin (%)
Net Gearing (%)
Net Interest Cover
About Chimeric Therapeutic (CHM.AX)
Research & News
There is currently no research for this stock.
Are you looking for the best stocks to buy in 2021? We’ve put together a free report on 5 stocks that we think are the best buys on the ASX right now. Download it instantly here.
Information is provided ‘as is’ and solely for information purposes, not for trading purposes or advice.
Want more Free Research?
Subscribe today for free and get an email with stocks to watch every Monday and new research every Thursday.
MF & Co. Asset Management
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.